Veraxa Biotech AG (NASDAQ: VRXA) Collaborates with Ardigen S.A. to Advance BiTAC Portfolio for Cancer Treatment
Veraxa Biotech AG (NASDAQ: VRXA) has announced a collaboration with Ardigen S.A. to advance its BiTAC portfolio for cancer treatment. The partnership will leverage AI tools to select dual cancer target pairs for Veraxa's BiTAC platform, which requires co-expression of two distinct targets on the same cancer cell for activation. This approach aims to minimize on-target, off-tumor toxicities associated with current cancer treatments.
Veraxa's CEO, Christoph Antz, highlighted the potential of AI processes in guiding the development strategy of BiTAC programs. The company's stock has shown volatility in recent months but has seen a positive return in the last week. Ardigen, an AI-driven computational partner, brings its expertise from over 700 discovery projects to support biotechnology and pharmaceutical organizations in drug discovery.
Veraxa, founded on scientific research from the European Molecular Biology Laboratory, is focused on developing antibody-based therapeutics, including bispecific T cell engagers and bispecific antibody drug conjugates. The financial terms of the collaboration with Ardigen were not disclosed in the announcement.
In addition to the collaboration, Veraxa Biotech AG has made significant strides in recent developments. The company appointed Carl von Halem as the Interim CFO and is actively seeking a permanent successor to support its growth. Veraxa plans to advance its BiTAC-based T cell engager VXA-102 to IND/CTA-ready status by early 2028, with a focus on targeting solid tumors. The company has also expanded its laboratory space in Heidelberg, Germany, to accommodate its growing R&D team and infrastructure needs.
These developments underscore Veraxa Biotech's commitment to advancing its therapeutic programs and expanding its operational capabilities. The company's focus on innovative approaches to cancer treatment and strategic collaborations position it for future success in the biotech industry.